Medicon Hellas S.A.

Medicon Hellas S.A.

MEDIC · AT · Healthcare / Drug Manufacturers - Specialty & Generic

3.15EUR+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close3.15
Open3.15
Day Range3.15 – 3.18
52-Week Range2.32 – 3.11
Volume2.50K
Market Cap13.17M
P/E (TTM)17.43
Forward P/E0.00
EPS0.171
Dividend Yield5.03%
Beta0.46
50-Day Avg2.76
200-Day Avg2.66

About

Medicon Hellas S.A. operates in the diagnostics industry. The company offers instruments, tests, and procedures for public and private hospitals, primary care centers, diagnostic centers, and private laboratories in Greece and internationally. The company distributes various analyzer sysytem for chemistry, immunochemistry and hematology labs, intensive care units, and point-of-care systems. It also produces reagents for various analyzers, such as specific protein and hematology, as well as clinical chemistry reagents comprising control and calibration materials, and tests. In addition, the company engages in the production of cosmetic and skin care products under the Miss Beaute brand name. Further, it develops and sells software for laboratory and medical applications, and supplies IT systems to healthcare providers. Additionally, the company remanufactures and resells chemistry, hematology, blood gas, and immunochemistry analyzers; and provides contract remanufacturing and diagnostics laboratory services. Medicon Hellas S.A. was founded in 1988 and is headquartered in Gerakas, Greece.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Dimotsantos S. Spyridon
  • Employees180
  • Headquarters5-7 Melitona Street, Gerakas, Greece, 153 44, Greece
  • Websitehttps://www.mediconsa.com

Leadership

  • Mr. Dimotsantos S. SpyridonCEO & Chairman of the Board · b. 1947
  • Mr. George KyridisChief Financial Officer · b. 1963
  • Mr. Georgios AntoniouDirector of Sales · b. 1972
  • Mr. Georgios DimotsantosDeputy CEO & Executive Director · b. 1989

Financials

Income Statement

Currency: EUR2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-31
Total Revenue11.03M11.46M13.01M12.70M13.77M13.45M15.27M21.51M20.77M
Growth (%)-+3.83%+13.56%-2.35%+8.40%-2.34%+13.51%+40.87%-3.41%
Cost of Revenue2.26M2.51M3.08M2.85M3.30M3.27M3.99M5.82M5.29M
Gross Profit8.78M8.94M9.93M9.85M10.47M10.18M11.28M15.69M15.48M
Gross Margin79.56%78.06%76.30%77.53%76.06%75.68%73.90%72.94%74.52%
Operating Expense7.29M6.69M7.04M7.90M8.30M9.07M9.69M10.68M11.65M
Operating Income1.49M2.25M2.89M1.95M2.18M1.11M1.59M5.00M3.83M
Operating Margin13.51%19.63%22.18%15.33%15.81%8.24%10.42%23.26%18.45%
Net Income699.38K1.67M1.17M1.72M1.83M775.17K756.60K3.04M2.53M
Net Income Margin6.34%14.62%8.96%13.52%13.29%5.76%4.96%14.14%12.20%
R&D274.53K280.90K341.26K514.13K670.03K----
R&D as % of Total Revenue2.49%2.45%2.62%4.05%4.87%----
Interest Expense00000000-
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%-

Balance Sheet

Currency: EUR2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-31
Total Assets28.71M31.02M33.02M30.66M27.21M28.53M28.61M31.19M31.81M
Total Liabilities25.12M25.68M26.90M22.82M17.53M18.27M17.58M16.85M14.85M
Total Equity3.29M4.96M6.12M7.84M9.68M10.26M11.03M14.34M16.95M
Cash3.16M2.39M4.04M4.42M6.22M6.07M7.20M--
Total Debt----13.48M13.81M12.57M--

Cash Flow

Currency: EUR2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-31
Operating Cash Flow1.79M-330.21K1.84M4.84M3.19M1.62M3.07M4.79M1.25M
Investing Cash Flow349.89K226.58K226.32K460.25K3.35M-1.54M-495.15K-315.54K-214.89K
Financing Cash Flow-953.61K-667.88K-421.87K-4.91M-4.74M-227.80K-1.45M-1.32M-1.18M
Capital Expenditure222.94K95.97K92.37K134.92K598.55K1.89M734.51K554.27K407.75K
Dividends Paid----114.34K114.34K114.34K114.34K106.41K

Earnings

Report DateMar 31, 2008Jun 30, 2008Sep 30, 2008Mar 31, 2009Jun 30, 2009Sep 30, 2009Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Dec 31, 2017
EPS Estimate----------------------
EPS Actual0.060.090.170.040.150.15-0.10-0.070.15-0.020.010.06-0.03-0.000.010.120.030.050.000.170.160.29
Surprise----------------------
Timing----------------------

Key Statistics & Ratios

Market Cap13.17M
Enterprise Value12.20M
Trailing P/E17.43
Forward P/E0.00
Price / Sales0.71
Price / Book0.00
EPS0.171
Book Value4.41
Revenue (TTM)18.63M
Gross Profit (TTM)13.64M
EBITDA4.17M
Profit Margin13.23%
Operating Margin17.85%
Return on Equity12.43%
Return on Assets5.71%
Shares Outstanding4.42M
Shares Float0
Beta0.46
Dividend Yield5.03%
Dividend Rate0.15
Payout Ratio0.00%

Dividends

20232×
0.04Jul 10, 20230.11Mar 1, 2023
20111×
0.21Jul 21, 2011
20101×
0.29Jul 6, 2010
20091×
0.29Jul 15, 2009
20081×
0.29Jul 14, 2008
20071×
0.29Jul 16, 2007
20061×
0.29Jul 11, 2006
20051×
0.32Jul 1, 2005
20041×
0.30Jul 12, 2004
20031×
0.30Jul 1, 2003
20021×
0.29Jul 2, 2002
20011×
0.16Aug 10, 2001

Stock Splits

  • Mar 4, 2015727:694
  • Jul 28, 200498163:89239
  • Aug 12, 200298163:89239